Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 4/20 | 0.40 |
| ▸ | MMP9 | P14780 | 4/20 | 0.40 |
| ▸ | MMP13 | P45452 | 4/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2913042 | 0.91 | CCR8 (0.42) | MEN1KMT2APOLBMMP1MMP9 | |
| SCHEMBL2915758 | 0.86 | CCR8 (0.42) | MEN1KMT2APOLBMMP1MMP9 | |
| SCHEMBL2942975 | 0.84 | SIGMAR1 (0.48) | MEN1KMT2APOLBMMP1MMP9 | |
| SCHEMBL2449927 | 0.83 | CCR8 (0.52) | MEN1KMT2AL3MBTL1CCR8ALDH1A1 | |
| SCHEMBL2913320 | 0.82 | HTR1A (0.39) | MEN1KMT2AMMP1MMP9MMP13 | |
| SCHEMBL2909365 | 0.80 | ALDH1A1 (0.41) | MEN1KMT2APOLBMMP1MMP9 | |
| SCHEMBL2912440 | 0.80 | HTR1A (0.41) | MEN1KMT2AMMP1MMP9MMP13 | |
| SCHEMBL13850486 | 0.78 | MCHR1 (0.38) | LMNAL3MBTL1CCR8ALDH1A1 | |
| SCHEMBL2914933 | 0.77 | MEN1 (0.39) | MEN1KMT2APOLBMMP1MMP9 | |
| SCHEMBL2449271 | 0.77 | KDM4E (0.54) | MEN1KMT2APOLBLMNACCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979355-B1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2010-08-18 | — | — | EP | disclosed |
| US-20090137610-A1 | SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2009-05-28 | — | — | US | disclosed |
| US-20090137610-A1 | SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2009-05-28 | — | — | US | disclosed |
| EP-1979355-A1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007087448-A1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137610-A1 | SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS | PPARD, PPARG, PPARA | MEN1 4719/4885KMT2A 3750/4885POLB 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.